Junshi Biosciences EGFR-HER3 bispecific antibody ADC has successfully advanced to its global Phase 2 clinical trial, ranking second in the world

CAR-T Digest - August 2020

Weekly Digest - January 2026

26 December 2025: Junshi Biosciences EGFR-HER3 bispecific antibody ADC has successfully advanced to its global Phase 2 clinical trial, ranking second in the world

Junshi Biosciences has recently registered a Phase 2 clinical trial for its EGFR/HER3 bispecific antibody drug JS212 on China’s NMPA drug clinical trial registration, marking a key step forward in its lung cancer development program
The study, which has already been initiated, will evaluate JS212 in combination with multiple immunotherapy and bispecific antibody regimens for patients with advanced lung cancer, making JS212 the second EGFR/HER3 bispecific antibody ADC globally to enter Phase 2 clinical development
The primary goal of the trial is to assess objective response rate in advanced lung cancer, with plans to enroll up to 846 patients, following regulatory approvals from China’s NMPA in January 2025 and the U.S. FDA, and trial initiation in March
JS212 is a humanized EGFR/HER3 bispecific antibody conjugated to irinotecan, and while detailed structural data have not yet been disclosed, it is believed to leverage proprietary ADC platform technologies developed through strategic collaboration
As EGFR/HER3 bispecific ADCs gain momentum globally-driven by recent late-stage clinical successes JS212 positions Junshi Biosciences to potentially reignite its innovation pipeline through synergistic combinations with its internal therapies